Showing results (1-10 of 377) with videos related to
Sort By:
Pageof 38
Ciba Foundation Symposium|January 1, 1994
Immunity to the HER-2/neu oncogenic proteinM L Disis, H Bernhard, J R Gralow, et al.Journal of Immunology (Baltimore, Md. : 1950)|May 1, 1996
Peptide-based, but not whole protein, vaccines elicit immunity to HER-2/neu, oncogenic self-proteinM L Disis, J R Gralow, H Bernhard, et al.Blood|July 1, 1996
Granulocyte-macrophage colony-stimulating factor: an effective adjuvant for protein and peptide-based vaccinesM L Disis, H Bernhard, F M Shiota, et al.Cancer Research|March 1, 1995
Generation of immunostimulatory dendritic cells from human CD34+ hematopoietic progenitor cells of the bone marrow and peripheral bloodH Bernhard, M L Disis, S Heimfeld, et al.Immunobiology|June 2, 2000
Dendritic cells lose ability to present protein antigen after stimulating antigen-specific T cell responses, despite upregulation of MHC class II expressionH Bernhard, E S Huseby, S L Hand, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 18, 1997
High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancerM L Disis, S M Pupa, J R Gralow, et al.Critical Reviews in Immunology|January 7, 1998
HER-2/neu oncogenic protein: issues in vaccine developmentM L Disis, M A CheeverCurrent Opinion in Immunology|October 1, 1996
Oncogenic proteins as tumor antigensM L Disis, M A CheeverAdvances in Cancer Research|January 1, 1997
HER-2/neu protein: a target for antigen-specific immunotherapy of human cancerM L Disis, M A CheeverImmunology|June 9, 1998
Human HER-2/neu protein immunization circumvents tolerance to rat neu: a vaccine strategy for 'self' tumour antigensM L Disis, F M Shiota, M A CheeverPageof 38